ArticleJournal of veterinary internal medicine
Metabolic Alterations Associated With Rapidly Progressive Chronic Kidney Disease in Cats.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) in cats often remains stable over time, but some cats experience progressive kidney dysfunction without an identifiable cause.
objectivesIdentify differences in serum and urine compounds related to tryptophan metabolism and gut-derived uremic toxins between cohorts with non-progressive and rapidly progressive CKD. ANIMALS: Forty-two client-owned cats diagnosed with CKD were divided into a rapid progression group (n = 8) and a non-progressive control group (n = 34).
methodsProspective cohort study with comparative analysis of predictors using targeted metabolomics. Rapid progression was defined as a 25% increase in serum creatinine concentration over 6 months.
resultsSerum metabolite ratios of the serotonin pathway showed promising potential for predicting rapid CKD progression in cats: L-tryptophan/5-hydroxytryptophan (area under curve [AUC]: 0.89; 95% CI: 0.78-1; p < 0.01; sensitivity: 85.7%; specificity: 78.8%) and serotonin/5-hydroxyindole-3-acetic acid (AUC: 0.83; 95% CI: 0.64-1; p < 0.01; sensitivity: 87.5%; specificity: 76.5%). Cats with rapidly progressive CKD had significantly lower baseline urinary indoxyl-sulfate (median [Interquartile range, IQR], 0.25 [0.07-0.46] vs. 0.53 [0.36-0.81]; p = 0.04) and p-cresyl-sulfate (median [IQR], 0.13 [0.01-0.79] vs. 0.83 [0.32-1.27]; p = 0.04). Logistic regression analysis identified an association between decreased urinary indoxyl-sulfate (odds ratio [OR]: 0.03; 95% CI: 0-1; p = 0.04) and rapidly progressive CKD, following a similar pattern after correcting for serum creatinine concentration (p = 0.06).
conclusionsMetabolites of the serotonin pathway: L-tryptophan, 5-hydroxytryptophan, and 5-hydroxyindole-3-acetic acid may serve as potential candidates for further predictive validation in CKD progression in cats. Decreased uremic toxin excretion in rapidly progressive CKD may underlie disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.